Oxford University Commences First Human Trials of COVID-19 Vaccine in South Africa
Oxford University in Partner with the University of Witwatersrand has rolled out the first human trials of COVID-19 vaccine in Africa in South Africa.
The trials that started on Wednesday will consist of 2,000 volunteers between the age of 18 to 65 years, this will include HIV positive patients. Together they will be administered the vaccine and monitored for 12 months to evaluate how well the vaccine protects them against COVID-19.
Shabir Madhi, a professor of vaccinology at Wits University and leader of the trial said, “Once 60% of the population, especially the adult population, becomes immune, we expect that effective reproductive rate to go under 1, which basically means the virus will still be around, it will still circulate, but its chain of transmission has been interrupted.”
South Africa is now the second country after Brazil to take part in the trial outside the United Kingdom where 4,000 people had previously volunteered.
The ChAdOx1 nCoV-19 vaccine, also known as AZD1222, was developed by Oxford University scientists, that are now working with AstraZeneca on development and production.
The trial has created a mixed feeling among Africans following decades of using Africans as guinea pigs for new medical trials.
Junior Mhlongo, a volunteer who received the vaccine at a hospital in Johannesburg, said: “I feel a little bit scared, but I want to know what is going on with this vaccine so that I can tell my friends and others.”
